Okubo, Yukari
Umezawa, Yoshinori
Sakurai, Shinya http://orcid.org/0000-0003-2631-8722
Hoshii, Naoki
Nakagawa, Hidemi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results
https://doi.org/10.1007/s13555-022-00741-x
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
https://doi.org/10.1007/s13555-021-00645-2
Funding for this research was provided by:
UCB Pharma
Article History
Received: 5 April 2022
Accepted: 26 April 2022
First Online: 27 May 2022